Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 7 C r1c2, r2c2; D E
Baxi AB et al. (2023)
|
Xla Wt + tgfbi MO
NF32 (in situ hybridization)
|
|
|
|
Fig.5.B,E,H,K
Tavares ALP et al. (2021)
|
Xla Wt + sobp
NF28-33/34 (in situ hybridization)
|
|
|
|
Fig.5.D,G,J
Tavares ALP et al. (2021)
|
Xla Wt + sobp CRISPR
NF28-33/34 (in situ hybridization)
|
|
|
|
Fig.5.M
Tavares ALP et al. (2021)
|
Xla Wt + sobp CRISPR
NF28-33/34 (RT-PCR)
|
|
|
|
Fig.5.C,F,I,L
Tavares ALP et al. (2021)
|
Xla Wt + sobpR651X
NF28-33/34 (in situ hybridization)
|
|
|
|
Fig. 4 D. Fig. 5 G
Shah AM et al. (2020)
|
Xla Wt + six1
NF28-32 (in situ hybridization)
|
|
branchiootorenal syndrome
branchiootic syndrome
|
|
Fig. 4 D
Shah AM et al. (2020)
|
Xla Wt + six1
NF28-32 (in situ hybridization)
|
|
branchiootorenal syndrome
branchiootic syndrome
|
|
Fig. 4 D
Shah AM et al. (2020)
|
Xla Wt + six1-R110W
NF28-32 (in situ hybridization)
|
|
branchiootic syndrome
branchiootorenal syndrome
|
|
Fig. 4 D, Fig. 5 H
Shah AM et al. (2020)
|
Xla Wt + six1-V17E
NF28-32 (in situ hybridization)
|
|
branchiootorenal syndrome
branchiootic syndrome
|
|
Fig. 4 D
Shah AM et al. (2020)
|
Xla Wt + six1-W122R
NF28-32 (in situ hybridization)
|
|
branchiootorenal syndrome
branchiootic syndrome
|